02.04.15
Farmingdale, N.Y-based Misonix Inc., a surgical device company that makes therapeutic ultrasonic products for surgical applications, has entered into an agreement with Aesculap Inc. to acquire back the rights to the remaining accounts, as of March 1, 2015, exclusively being managed by Aesculap for the Misonix Bonescalpel ultrasonic bone cutting system.
Since December 2012, under a non-exclusive distribution agreement, Aesculap retained the right to sell Bonescalpel disposables in the United States to certain, limited hospital accounts which are covered by binding supply agreements for varying periods of time, but not to exceed 3 years. The device is an ultrasonic surgical system used for tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures.
“We are thankful to Aesculap and their professional management of, and efforts in, servicing these strategically important accounts,” said Michael A. McManus, Jr., president and CEO of Misonix. “This new agreement moves Misonix an important additional step further along the path of complete control of Bonescalpel distribution in the United States through the company’s own growing network of sales representatives.”
Since December 2012, under a non-exclusive distribution agreement, Aesculap retained the right to sell Bonescalpel disposables in the United States to certain, limited hospital accounts which are covered by binding supply agreements for varying periods of time, but not to exceed 3 years. The device is an ultrasonic surgical system used for tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures.
“We are thankful to Aesculap and their professional management of, and efforts in, servicing these strategically important accounts,” said Michael A. McManus, Jr., president and CEO of Misonix. “This new agreement moves Misonix an important additional step further along the path of complete control of Bonescalpel distribution in the United States through the company’s own growing network of sales representatives.”